Official Title
COVID-19 Outcomes: A Retrospective Study of Neurological Manifestations and Associated Symptoms (The Philippine CORONA Study)
Brief Summary

This study will determine the neurological profile and predictors of outcomes in patients with COVID-19 disease in the Philippines. It will also evaluate if there is significant difference between COVID-19 patients with neurological manifestations compared to those COVID-19 patients without neurological manifestations in terms of various prespecified clinical outcomes. Furthermore, the likelihood of these outcomes in COVID-19 patients with neurological manifestations compared to those without neurological manifestation will be determined in this study.

Detailed Description

This quantitative, retrospective, cohort study will determine the following: 1) demographic,
clinical and neurological profile of patients with COVID-19 disease in the Philippines; 2)
the frequency of neurological symptoms and new-onset neurological disorders/complications in
patients with COVID-19 disease; 3) the neurological manifestations that are significant
predictors of mortality, respiratory failure, duration of ventilator dependence, intensive
care unit (ICU) admission, length of ICU stay, and length of hospital stay; 4) if there is
significant difference between COVID-19 patients with neurological manifestations compared to
those COVID-19 patients without neurological manifestations in terms of mortality,
respiratory failure, duration of ventilator dependence, ICU admission, length of ICU stay and
length of hospital stay; and 5) the likelihood of mortality, respiratory failure and ICU
admission in COVID-19 patients with neurological manifestations compared to those without
neurological manifestations.

Unknown status
Coronavirus Disease 2019
Eligibility Criteria

Inclusion Criteria:

- Cases confirmed by testing approved patient samples (i.e. nasal swabs, sputum,
bronchoalveolar lavage fluid) employing the real-time reverse transcriptase polymerase
chain reaction (RT-PCR) from COVID-19 testing centers accredited by the DOH;

- adult patients at least 19 years of age;

- male or female;

- cases with clinical symptoms and signs attributable to COVID-19 disease (i.e.
respiratory as well as non-respiratory clinical signs and symptoms), with or without
the availability of ancillary tests (i.e. complete blood count, chest x-ray); cases
with disposition (i.e. discharged or died) at the end of the study period.

Exclusion Criteria:

- Pediatric patients ≤18 years

- Cases with conditions of diseases caused by other organisms (i.e. bacteria, other
viruses, fungi, etc.) or caused by other pathologies unrelated to COVID-19 disease
(i.e., trauma).

Eligibility Gender
All
Eligibility Age
Minimum: 19 Years ~ Maximum: N/A
Countries
Philippines
Locations

Philippine General Hospital - University of the Philippines Manila
Manila, Philippines

Investigator: Adrian I Espiritu, MD
Contact: +639258520341
aiespiritu@up.edu.ph

Contacts

Adrian I Espiritu, MD
+639258520341
aiespiritu@up.edu.ph

Roland Dominic G Jamora, MD
+639985438062
rgjamora@up.edu.ph

Adrian I Espiritu, MD, Principal Investigator
University of the Philippines

University of the Philippines
NCT Number
Keywords
Covid-19
neurological manifestations
Outcomes
cohort study
MeSH Terms
COVID-19